Bristol’s recent wins
Bristol-Myers Squibb (BMY) is primarily immuno-oncology focused company. Its key drug, Opdivo, has been approved for treating all second-line NSCLC (non-small cell lung cancer), second-line renal cancer, head and neck cancer, melanoma, and cHL (classical Hodgkin lymphoma) patients. And an Opdivo-Yervoy combination has already been approved for treating first-line metastatic melanoma.
Recent regulatory advances for Opdivo
Opdivo’s significant regulatory advances over the past quarter include approval for head and neck cancer indications, a positive CHMP (Committee for Medicinal Products for Human Use) opinion for the indication of cHL in Europe, and the acceptance of its priority review application by the FDA (US Food and Drug Administration) for advanced bladder cancer. Opdivo’s advanced bladder cancer application has also been validated in Europe.
Bristol is using Opdivo as a backbone for developing multiple combinations. To understand Bristol’s future immune-oncology development strategy, please read “Bristol-Myers Squibb’s Strategies to Dominate Immuno-Oncology Market.”
On November 10, Bristol announced that its phase 3 trial, ONO-4538-12 met its primary endpoint of OS (overall survival) in gastric cancer patients. This trail was conducted in Japan, Korea, and Taiwan and was in partnership with Ono Pharmaceutical (OPHLY).
Notably, investing in the PowerShares Dynamic Pharmaceuticals ETF (PJP) will offer you diversified exposure to Bristol. PJP invests ~5.3% of its assets in Bristol and ~6.1%, ~5.5% and ~5.2% of its assets in Celgene (CELG), Merck (MRK), and Gilead Sciences (GILD), respectively.
Continue to the next and final part of this series for a look at the latest analyst recommendations for Bristol.